European award for medicinal chemists: New active ingredients for the treatment of infections

Martin Empting works towards the development of new active substances that can be used to treat bacterial and viral infections. He has now been awarded the Young Medicinal Chemist in Academia Prize by the European Federation of Medicinal Chemistry (EFMC) as a runner-up. This prize is aimed at young chemists who are pursuing a career in academic research.

Background Research:
Martin Empting is a significant figure in the arena of medicinal chemistry. He is intensely focused on creating new active ingredients, which could be instrumental in managing bacterial and viral infections. The European Federation for Medicinal Chemistry (EFMC) has recognized his efforts and rewarded him with the Young Medicinal Chemist in Academia Prize as runner-up.

Medicinal Chemistry is a specialized area of study within the domain of chemistry. It significantly deals with the development, discovery, and design of new pharmaceutical drugs. Generally, practitioners apply their chemistry expertise to discover and develop new therapeutics.

The European Federation for Medicical Chemistry (EFMC) is an independent body representing medicinal chemistry societies from Europe and Israel. Their goal includes promoting advancements in medical research and recognising young talents through awards like The Young Medicinal Chemist in Academia Prize.

FAQs:

1. Who is Martin Empting?
– Martin Empting is a medicinal chemist who specializes in developing new active substances to treat bacterial and viral infections.

2. What did Martin Empting receive?
– He received the Young Medicinal Chemist in Academia Prize from the European Federation for Medical Chemistry (EFMC).

3.Why was he awarded this prize?
– Martin was awarded this prize because of his commitment to developing new therapeutic agents that can assist significantly against bacterial or viral infections.

4.What does ‚Young Medicinal Chemist In Academia‘ Award signify?
– The award acknowledges young chemists making strong advancements into academic research oriented towards medicinal chemistry specializations.

5.What do we mean by „active substances“ against bacteria or viruses?
– „Active substances“ refers to components that are effective against diseases- they can kill bacteria/viruses or hinder their replication thereby treating infection effectively.

6.How do these awards impact scientists like Martin Empting?
– These awards provide recognition on an international scale and often open up wider opportunities for recipients. They also offer prestige, enabling the scientists to seek funding more easily or form new collaborations.

7.Who are EFMC?
– EFMC is an independent association representing medicinal chemistry societies from Europe and Israel. They aim at promoting the advancement of research in this field.

8.What is Medicinal Chemistry?
– Medicinal Chemistry can be defined as a branch within chemistry focused on discovery, development, identification and interpretation of new therapeutic agents or drugs.

9.Why is it important to develop new active substances for infections?
– The development of new active substances against infections is crucial due to the rise in drug-resistant microbial strains. It’s necessary to ensure effective treatments for bacterial and viral infections continue being available.

10.How does medicinal chemistry contribute towards improving health conditions?
– Medicinal chemistry contributes towards improving health by helping discover and create novel drugs or treatments that can deal with various diseases effectively.

Originamitteilung:

Martin Empting works towards the development of new active substances that can be used to treat bacterial and viral infections. He has now been awarded the Young Medicinal Chemist in Academia Prize by the European Federation of Medicinal Chemistry (EFMC) as a runner-up. This prize is aimed at young chemists who are pursuing a career in academic research.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

ERC Consolidator Grant für Georg Winter gibt rasant wachsendem Forschungsfeld weiteren Auftrieb

Maßgeschneiderte kleine Moleküle, die sich an Krebs verursachende Proteine heften und Tumorzellen dadurch unschädlich machen – das ist Georg Winters Spezialgebiet, in dem sich der Forschungsgruppenleiter am CeMM der ÖAW als weltweit führender Experten etabliert hat. Sein neuestes ERC CoG Projekt GENEomorph hebt seine Forschung auf eine neue Ebene: Anstatt Krebsproteine wie bisher für die zelluläre Müllabfuhr zu markieren, nimmt Winter mit seinen Design-Molekülen nun sogenannte Transkriptionsfaktoren ins Visier, ein vielversprechender Weg für neue Medikamente. Das sieht auch der Europäische Forschungsrat ERC so: Er fördert dieses Projekt in den nächsten fünf Jahren mit 1,9 Millionen Euro.

Read More